Also in the syndicate are venture capital firms Crossroad Fund, Medica Venture Partners, SCP-Vitalife and the Technion Investment Opportunities Fund, the investment fund of the Technion - Israel Institute of Technology.
Regentis Biomaterials, a US and Israel-based developer of hydrogels for human tissue regeneration, has raised $10m in its series C round from a consortium including Netherlands-based industrial group Royal DSM. The $10m will be used to develop Regentis’s European presence and expand its ongoing clinical efforts of GelrinC, a biodegradable implant that enhances growth of…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
